Atlantic Union Bankshares Corp Purchases 32,645 Shares of Pfizer Inc. $PFE

Atlantic Union Bankshares Corp increased its position in shares of Pfizer Inc. (NYSE:PFE) by 32.2% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 133,990 shares of the biopharmaceutical company’s stock after purchasing an additional 32,645 shares during the quarter. Atlantic Union Bankshares Corp’s holdings in Pfizer were worth $3,414,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Pfizer during the second quarter worth approximately $2,270,157,000. Vanguard Group Inc. boosted its stake in shares of Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after buying an additional 10,198,330 shares during the period. Arrowstreet Capital Limited Partnership grew its position in Pfizer by 43.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock worth $453,747,000 after buying an additional 5,662,309 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Pfizer by 75.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock worth $221,398,000 after acquiring an additional 3,722,531 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in Pfizer by 84.9% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock valued at $183,302,000 after acquiring an additional 3,472,240 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beat on both EPS and revenue — Pfizer reported $0.66 EPS vs. $0.57 expected and revenue of $17.56B vs. ~$16.9B consensus, showing resilient demand for older drugs like Eliquis that helped offset COVID declines. Reuters: Pfizer beats fourth-quarter profit estimates
• Positive Sentiment: Obesity drug shows promise — Phase 2b data for PF’3944 (MET‑097i) showed up to ~12% weight loss with monthly dosing, supporting Pfizer’s strategy to build an obesity franchise and reduce reliance on COVID sales. BusinessWire: Phase 2b obesity trial results
• Neutral Sentiment: Company reaffirmed 2026 guidance — Pfizer reiterated its modest outlook (under $3 EPS) and reiterated strategic shift post‑Covid; that reduces uncertainty about management’s targets but signals limited near‑term upside. BusinessWire: Press release
• Neutral Sentiment: Analyst stance mixed — some firms (e.g., Goldman Sachs) maintain neutral ratings citing margin pressure and patent risks, keeping expectations tempered. InsiderMonkey: Goldman Sachs note
• Negative Sentiment: Profit and revenue headwinds flagged — management flagged an expected profit decline and analysts note a ~$1.5B near‑term hit from patent cliffs and lower COVID product demand, weighing on valuation. Seeking Alpha: revenue decline / patent cliff note
• Negative Sentiment: Safety and differentiation questions around the obesity drug — some coverage raised questions about side effects and whether monthly dosing will compete with established weekly GLP‑1 drugs (e.g., Lilly’s Zepbound), muting investor enthusiasm. MSN: safety questions
• Negative Sentiment: Vaccines and Covid sales continue to drag — ongoing declines in Covid vaccine/antiviral revenue are pressuring top‑line growth despite gains elsewhere. FT: vaccines weigh on sales

Analysts Set New Price Targets

A number of research analysts recently commented on the company. UBS Group began coverage on Pfizer in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target on the stock. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 price target on shares of Pfizer in a report on Friday, October 31st. Cantor Fitzgerald increased their price target on shares of Pfizer from $24.00 to $27.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 27th. Finally, Zacks Research downgraded shares of Pfizer from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.06.

Pfizer Trading Down 3.3%

Shares of Pfizer stock opened at $25.77 on Wednesday. The firm has a market capitalization of $146.53 billion, a PE ratio of 14.98 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The firm’s 50 day moving average is $25.54 and its 200 day moving average is $25.06. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. The firm’s revenue was down 1.2% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s payout ratio is currently 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.